<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00061997</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000302633</org_study_id>
    <secondary_id>BCCA-U98-0411</secondary_id>
    <secondary_id>BCCA-C02-0298</secondary_id>
    <nct_id>NCT00061997</nct_id>
  </id_info>
  <brief_title>Inositol in Preventing Lung Cancer in Patients With Bronchial Epithelial Dysplasia Who Are Current or Former Smokers</brief_title>
  <official_title>A Phase I Study Of The Safety Of Myo-Inositol As A Chemopreventive Agent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the&#xD;
      development or recurrence of cancer. Inositol may be effective in preventing the development&#xD;
      of lung cancer in patients with bronchial epithelial dysplasia.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of inositol in&#xD;
      preventing lung cancer in current or former smokers with bronchial epithelial dysplasia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety of inositol for the prevention of lung cancer in patients with&#xD;
           bronchial epithelial dysplasia who are current or former smokers.&#xD;
&#xD;
        -  Determine the potential efficacy of this drug in regression of existing dysplastic&#xD;
           lesions or prevention of appearance of new dysplastic lesions in these patients.&#xD;
&#xD;
        -  Determine whether intake of this drug can facilitate smoking cessation in patients who&#xD;
           are current smokers.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive oral inositol twice daily. Treatment continues for 1 or 3 months in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-12 patients receive escalating doses of inositol until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 12&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      Once the MTD is determined, 10 patients are treated with inositol twice daily at the MTD for&#xD;
      3 months in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 1 month.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-28 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <condition>Precancerous Condition</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>inositol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of persistent bronchial dysplasia despite regular twice-daily treatment with&#xD;
             inhaled budesonide for 6 or 12 months on protocol BCCA-CIC-98-37&#xD;
&#xD;
          -  Current or former smokers who have smoked at least 30 pack years&#xD;
&#xD;
          -  Sputum cells showing AIC atypia by computer-assisted image analysis&#xD;
&#xD;
          -  At least 2 abnormal sites on fluorescence bronchoscopy (red/green ratio at least 0.45)&#xD;
             suspicious for bronchial dysplasia&#xD;
&#xD;
               -  At least 1 site confirmed by bronchial biopsy&#xD;
&#xD;
               -  Solitary dysplastic lesion allowed provided the diameter is greater than 1.5 mm&#xD;
&#xD;
          -  No invasive cancer on bronchoscopy or abnormal low-dose spiral CT scan suspicious for&#xD;
             lung cancer&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  40 to 74&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Hematologic function normal&#xD;
&#xD;
          -  No bleeding disorder&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Liver function normal&#xD;
&#xD;
          -  Liver enzymes no greater than upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Renal function normal&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No acute or chronic respiratory failure&#xD;
&#xD;
          -  No acute bronchitis or pneumonia within the past month&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Fasting glucose less than 144 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Willing to have a bronchoscopy&#xD;
&#xD;
          -  No schizophrenia&#xD;
&#xD;
          -  No bipolar disorder&#xD;
&#xD;
          -  No diabetes&#xD;
&#xD;
          -  No known reaction to topical xylocaine&#xD;
&#xD;
          -  No other medical condition that would jeopardize patient safety during study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior surgery for lung cancer&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent lithium&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Lam, MD</last_name>
    <role>Study Chair</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2005</verification_date>
  <study_first_submitted>June 5, 2003</study_first_submitted>
  <study_first_submitted_qc>June 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2003</study_first_posted>
  <last_update_submitted>February 1, 2010</last_update_submitted>
  <last_update_submitted_qc>February 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2010</last_update_posted>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>small cell lung cancer</keyword>
  <keyword>precancerous condition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

